Analyst firms · Leerink Partners · HCAT
Leerink Partners HCAT price target and rating history
Health Catalyst Inc (HCAT) · Technology
Leerink Partners rates Health Catalyst Inc (HCAT) Outperform with a $48 price target, as of its latest action on Mar 2, 2022. It has published 3 rating actions on HCAT since June 2021, including 0 upgrades and 0 downgrades.
- Current rating
- Outperform
- Price target
- $48
- Median target, all firms
- Too few
- Actions on HCAT
- 3
Leerink Partners price target on HCAT
Every Leerink Partners rating on HCAT
- Mar 2, 2022
- Aug 6, 2021
- Jun 30, 2021
How other firms rate HCAT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Hold | $1.80 | Aug 21, 2026 |
| Wells Fargo | Equal Weight | $1 | Mar 18, 2026 |
Questions about Leerink Partners and HCAT
- What is Leerink Partners's price target for HCAT?
- Leerink Partners's latest stated price target for Health Catalyst Inc (HCAT) is $48, from its action on Mar 2, 2022.
- What is Leerink Partners's rating on HCAT?
- Leerink Partners rates HCAT Outperform, a bullish rating, as of Mar 2, 2022.
- When did Leerink Partners last change its view on HCAT?
- On Mar 2, 2022, Leerink Partners cuts its price target to $48 from $64, keeps Outperform.
More HCAT rating histories
All Leerink Partners ratingsHCAT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.